Biotek-snakken — September 2021
-
Nej ingen ny info omkring IND, men jeg tror det kommer senere på året, i deres corporate presentation er det i hvert fald angivet som et mål at præsentere prækliniske data og IND projections i H2 2021 for STRO-003
-
Vor Biopharma Says FDA Grants Fast Track Designation To VOR33 For Acute Myeloid Leukemia https://www.proinvestor.com/investornyt/702563/vor-biopharma-says-fda-grants-fast-track-designation-to-vor33-for-acute-myeloid-leukemia
-
Bonesupport Shares Expected to Drop at Least 10% After Major Study Setback https://www.proinvestor.com/investornyt/702553/bonesupport-shares-expected-to-drop-at-least-10-after-major-study-setback
-
Angående ROR1 så var BI også interesserede: Boehringer Ingelheim has committed up to $1.45 billion, including milestones, to acquire NBE Therapeutics and its ROR1-targeted antibody–drug conjugate (ADC) NBE-002. The deal was inked just a month after Merck plunked down $2.75 billion in cash to acquire VelosBio and its ROR1 ADC VLS-101.
-
STENOCARE's world-class cultivation facility is completed: https://www.proinvestor.com/index.php?p=debat_1&postid=96871
-
3 Top Healthcare Stocks to Buy for September
https://www.proinvestor.com/investornyt/702610/3-top-healthcare-stocks-to-buy-for-september
-
'It's game over. It's mRNA or nothing:' Expert on future of vaccines https://finance.yahoo.com/news/its-game-over-its-m-rna-or-nothing-expert-on-future-of-vaccines-200508222.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAM7dOhgASE4wmIpJqtc6TeOC8J6JKLZ7sZ35Fhj7ru1eO_U-qnIC8AohVYibAljwumlWdKoq3WCygD0iHceb-SUzKcMeL40qMGqXtxYYEDUXXS3eWrHaoDptdFycr4IVTG_HpHDvCuSVstpmPBtKKggnG1HQmNjEgvaYr7TJN4pj
-
Lassevedel - skrev til Sutro og de bekræftede det du også skrev, at STRO-003 bliver offentliggjort senere på året med timelines for IND. Desuden bekræftede de at STRO-003 bliver en af de nye targets, så mest oplagt er vel 5T4/CD3, da den synes længst fremme
-
Servicemeddelelse
Nu har Proinvestor løbende "updates reports on gurus" fra Validea i vort Nasdaq US newsfeed.
Validea er en investeringsforskningstjeneste, der følger de offentliggjorte strategier for investeringslegender. Validea tilbyder både aktieanalyse og modelporteføljer baseret på guruer, der har overgået markedet på lang sigt, herunder Warren Buffett, Benjamin Graham, Peter Lynch og Martin Zweig.
-
These Promising Clinical Results on Tezepelumab Could Be Huge for Amgen Investors https://www.proinvestor.com/investornyt/703071/these-promising-clinical-results-could-be-huge-for-amgen-investors
-
2 Top Biotech Stocks to Buy Right Now
https://www.proinvestor.com/investornyt/703119/2-top-biotech-stocks-to-buy-right-now
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind